Multicenter clinical trial of Percutaneous Peptide Immunization for malignant melanoma patients
Phase 2
- Conditions
- malignant melanoma
- Registration Number
- JPRN-UMIN000005706
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not received chemo therapy within a month. No big metastatic lesion in the liver or in the brain. Not pregnant. Not receiving immunosuppressive agent. No eczematous lesion on the skin. No hepatitis. No collagen disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival by status of tumor specific cytotoxic T cell induction
- Secondary Outcome Measures
Name Time Method Induction rate of tumor specific cytotoxic T cell. Tumor regression Adverse events